Oncoinvent ASA

OB:ONCIN Stock Report

Market Cap: NOK 172.0m

Oncoinvent Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Oystein Soug

Chief executive officer

NOK 2.8m

Total compensation

CEO salary percentage32.89%
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure1.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Oystein Soug's remuneration changed compared to Oncoinvent's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024NOK 3mNOK 916k

-NOK 140m

Compensation vs Market: Oystein's total compensation ($USD268.89K) is about average for companies of similar size in the Norwegian market ($USD337.68K).

Compensation vs Earnings: Insufficient data to compare Oystein's compensation with company performance.

CEO

Oystein Soug (55 yo)

less than a year

Tenure

NOK 2,785,000

Compensation

Mr. Oystein Soug, M.Sc, serves as Chief Executive Director of Oncoinvent AS since September 01, 2024. Mr. Soug was Chief Executive Director of Arxx Therapeutics. He served as an Interim Chief Financial Off...

Leadership Team

NamePositionTenureCompensationOwnership
Oystein Soug
Chief Executive Officerless than a yearNOK 2.79mno data
Tore Kvam
Chief Financial Officerno dataNOK 1.86mno data
Gro Hjellum
Chief Operating Officerless than a yearNOK 2.03mno data
Kristine Lofthus
Chief Production Officerno dataNOK 1.56mno data
Stian Brekke
Head of Regulatory Affairs3.6yrsNOK 1.45mno data
Kari Myren
Chief Medical Officer3.6yrsNOK 2.17mno data
Anne Alvik
Head of Quality Assurance & Employee Representative Directorno dataNOK 1.39m0.013%
NOK 23.2k
Anne-Kirsti Aksnes
Chief Clinical Officerless than a yearNOK 1.98mno data
Froydis Schulz
Head of Health Safety & Environmentless than a yearno datano data
Ingjerd Eika
Head of Quality Controlless than a yearno datano data

0.8yrs

Average Tenure

Experienced Management: ONCIN's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anne Alvik
Head of Quality Assurance & Employee Representative Directorno dataNOK 1.39m0.013%
NOK 23.2k
Roy Larsen
Chairman of Scientific & Clinical Advisory Board1.1yrsNOK 367.00k0.69%
NOK 1.2m
Øyvind Bruland
Member of Scientific Clinical Advisory Boardno dataNOK 298.00kno data
Hilde Steineger
Director1.1yrsno datano data
Charles O'Bryan-Tear
Chair of the Board1.1yrsno data0.36%
NOK 616.0k
Ingrid Akay
Director1.1yrsno data0.25%
NOK 434.9k
Kari Gronas
Director1.1yrsno data0.077%
NOK 132.0k
Orlando Oliveira
Director1.1yrsno datano data

1.1yrs

Average Tenure

58yo

Average Age

Experienced Board: ONCIN's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 19:50
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncoinvent ASA is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geir HolomDNB Markets